Effects of Different Doses of Ticagrelor Combined with Atorvastatin Calcium Tablets on Hemorheology Cardiac Function and Serum MMP-9 and IGF-1 in Patients with Coronary Heart Disease UAP
WANG Wenjuan, LI Gonghui, et al
Zhujiang Hospital, Southern Medical University, Guangdong Guangzhou 510510, China
Abstract：Objective: To explore the effects of different doses of ticagrelor combined with atorvastatin calcium tablets on hemorheology, cardiac function and serum matrix metalloprotein-9 (MMP- 9), the effect of insulin-like growth factors-1 (IGF-1). Methods: A total of 117 patients with coronary heart disease UAP who were treated in our hospital from November 2020 to November 2021 were prospectively selected as the research subjects, and were divided into groups A and B by simple random coin tossing method, and finally 61 patients in group A and 56 patients in group B were included. The patients in group B were given 90mg ticagrelor + atorvastatin calcium tablets on the basis of conventional treatment, and the patients in group A were given 45mg ticagrelor + atorvastatin calcium tablets on the basis of conventional treatment , the two groups of patients were treated continuously for 1 month. The rheology (whole blood viscosity (WBV), plasma viscosity (PV)), cardiac function (left ventricular ejection fractions (LVEF), left ventricular end diastolic diameter (LVEDD) and serum MMP-9, LVEDD) were compared between the two groups before and after 1 month of treatment(LVEF), left ventricular end diastolic diameter (LVEDD), interventricular septum thickness (IVST)) and serum MMP-9 and IGF-1 levels. Results: The results of repeated measures variance showed that the comparison between the WBV and PV levels at different points of treatment in both groups was statistically significant with time factor as the source, between-subjects effect with group as the source and within-subjects effect with time and group interaction as the source, P<0.05; after 1 month of treatment, the WBV and PV levels decreased in both groups and were lower in group A than in group B, P<0.05; The results of repeated measurement variance showed that the comparison of LVEF, LVEDD, and IVST levels at different points of treatment in both groups was statistically significant with time factor as the source, between-subjects effect with group as the source and within-subjects effect with time and group interaction as the source, P<0.05; after 1 month of treatment, LVEF levels increased in both groups and were higher in group A than in group B, LVEDD and IVST levels decreased and were lower in group A than in group B, P<0.05. Repeated measurement variance results showed that the two groups of patients were not treated well. At the same time, the MMP-9 and IGF-1 levels at the same time points were compared between the inter-subject effect with the time factor as the source, the group as the source, and the intra-subject effect with the interaction between time and group as the source, P<0.05; after one month treatment, the levels of MMP-9 in both groups decreased and lower in group A than in group B, while the levels of IGF-1 increased and higher in group A than in group B, P<0.05.Conclusion: Different doses of ticagrelor combined with atorvastatin calcium tablets have certain therapeutic effects on patients with coronary heart disease UAP, but the patients in the low-dose group have better improvement in blood rheology and cardiac function, and can significantly reduce MMP-9 And improve the level of IGF-1, which is worthy of clinical reference.
王文娟, 李功辉, 罗宇文. 不同剂量替格瑞洛联合阿托伐他汀钙片对冠心病UAP患者血液流变学心功能及血清MMP-9 IGF-1的影响[J]. 河北医学, 2022, 28(8): 1383-1386.
WANG Wenjuan, LI Gonghui, et al. Effects of Different Doses of Ticagrelor Combined with Atorvastatin Calcium Tablets on Hemorheology Cardiac Function and Serum MMP-9 and IGF-1 in Patients with Coronary Heart Disease UAP. HeBei Med, 2022, 28(8): 1383-1386.
[1] 王杰,单裕清,胡伟,等.冠状动脉CT血管成像定量参数与老年冠心病患者病情严重程度的相关性[J].中华老年心脑血管病杂志,2020,22(2):115-118. [2] 黄建,江钟立,沈璐.小而密低密度脂蛋白水平与他汀类药物剂量及缺血性卒中复发关系的研究[J].河北医科大学学报,2021,42(8):950-955. [3] 王婧,张英强,徐艳娟,等.替格瑞洛治疗冠心病不稳定型心绞痛对人血浆脂蛋白相关磷脂酶A2及心功能的影响[J].河北医学,2021,27(7):1227-1232. [4] Deveci OS,Ozmen C,Karaaslan MB,et al.Could serum copeptin level be an indicator of coronary artery disease severity in patients with unstable angina[J].Int Heart,2021,62(3):528-533. [5] Liu X,Zhang Y,Jin F,et al.Correlation between GPR,MHR and elderly essential hypertension with unstable angina pectoris[J].Zhong Nan Da Xue Xue Bao Yi Xue Ban,2021,46(4):373-378. [6] 吕涛,王凯,王新明.血流储备分数测定对冠心病介入治疗及预后的临床价值[J].中西医结合心脑血管病杂志,2021,19(11):1884-1887. [7] 冯逸清,李飞,边娟,等.阿托伐他汀钙片联合替格瑞洛片治疗冠心病不稳定型心绞痛患者的临床研究[J].中国临床药理学杂志,2020,36(19):2972-2975. [8] 何彪华,冯胜红,方翔,等.不同剂量替格瑞洛对稳定型冠心病患者血小板功能的影响及不良反应分析[J].四川生理科学杂志,2020,42(3):256-260.
2022, Vol. 28 
冀公网安备13080202000677号